Breast Cancer Research and Treatment

Article	Citations
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	119
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	92
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	72
Prognostic and predictive impact of NOTCH1 in early breast cancer	66
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	59
Surveillance mammography after treatment for male breast cancer	59
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	57
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	56
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	53
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	47
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	46
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	46
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	42
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	38
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	37
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	37
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	37
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	36
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study	36
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)	34
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience	34
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	32
Endocrine adherence in male versus female breast cancer: a seer-medicare review	32
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	30
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	30

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	29
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	29
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	29
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	29
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer	27
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients	26
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy	26
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	26
Integrating SENOMAC and AMAROS: a call for de-escalation	25
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	25
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	25
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	25
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores	24
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer	24
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer	24
Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population	23
Clinical trials of immunotherapy in triple-negative breast cancer	23
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study	22
Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy	22
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021	21
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings	21
Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception	21
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients	21
Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study	21
Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea	21
Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer	21
A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer	20
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry	20
A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients	20
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?	20
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a media	20
New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery	20
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy	19
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression	19
Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients	19
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al	19
Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations	19
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	19
Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management	19
Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies	19
Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis	18
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms	18
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent ki	18
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk	18
Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019	18
Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 2017	18
Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study	18
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study	18
Hormone-associated dietary patterns and premenopausal breast cancer risk	17
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study	17

Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis	17
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy	17
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer	17
Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer	16
Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort	16
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice	16
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma	16
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263	16
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial	16
Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene	16
Correlation analysis between shear-wave elastography and pathological profiles in breast cancer	16
Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue	15
Strict definition of a small tumor in breast cancer should be revisited	15
Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens	15
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer regist	15
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer	15
Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan	15
Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer	15
Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer	15
Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma	15
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany	15
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction	15
Penetrance of male breast cancer susceptibility genes: a systematic review	15
Multi-omics portrait of ductal carcinoma in situ in young women	15
Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer	15
HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles	15
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?	14
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review	14
Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis	14
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study	14
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status	14
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study	14
A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells	14
Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases	14
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world	14
Omission of multimodal therapy in older adults with high-risk breast cancer	14
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis	14
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy—results of the multicenter UMBRELLA breast cancer cohort	14
Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort	14
Male breast cancer: a multicenter study to provide a guide for proper management	14
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer	14
A mixed method study of medical oncologists’ perceived barriers and motivators to addressing long-term effects in breast cancer survivors	14
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)	14
Clinical and sociodemographic determinants of older breast cancer survivors’ reports of receiving advice about exercise	14
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients	14
Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study	14
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer	13
Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)	13
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study	13
Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention	13
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities	13
Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial	13
Association of body composition and surgical outcomes in patients with early-stage breast cancer	13
Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients	13
Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics	13
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis	13
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases	13
Psychological consequences of MRI-based screening among women with strong family histories of breast cancer	13
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer	13
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium	13
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer	13
Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016	13
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors	13
Influence of rurality on lymph node assessment among women diagnosed with ductal carcinoma in situ and treated with mastectomy, SEER 2000–2015	13
Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins	12
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer	12
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit	12
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study	12
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)	12
Letter to the editor regarding “Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany”	12
An overview of genetic services delivery for hereditary breast cancer	12
High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors	12
PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer	12
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative br	12
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast)	12
Changes in the survival of patients with breast cancer: Poland, 2000–2019	12
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials	12
Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital	12
Breast cancer resistance mechanisms: challenges to immunotherapy	12
Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer	12

Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study	12
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center	12
Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer	12
Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials	12
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis	12
Organoid models derived from patients with malignant phyllodes tumor of the breast	12
Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy	12
A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast	12
Diagnostic performance of screening mammography according to menstrual cycle among Asian women	11
The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer	11
Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis	11
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer	11
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis	11
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer	11
Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy	11
Lumpectomy surgery for large ductal carcinoma in situ	11
Reply to: “Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)”	11
Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression	11
Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data	11
Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study	11
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey	11
BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses	11
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer	11
Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis	11
Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and	11
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy	11
Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis	11
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases	11
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy	11
Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique	11
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age	11
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers	11
The importance of SOCS1 − 1478 CA/del polymorphism and expression in breast cancer: a case–control study in the north of Iran	11
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark	11
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome	11
Correction: The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection	11
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial	11
Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors	11
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study	11
Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting	11
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2− negative breast cancer	11
Estimating the incidence of breast cancer recurrence using administrative data	10
Perceptions of breast cancer risk after breast density notification in a population-based screening program	10
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41	10
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series	10
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer	10
Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)	10
Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?	10
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy	10
Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study	10
Limitations of locoregional and distant recurrence analysis after neoadjuvant chemotherapy	10
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study	10
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review	10
Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study	10
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study	10
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients	10
Impact of diabetes on surgery and radiotherapy for breast cancer	10
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer	10
Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study	10
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease	10
Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics	10
Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review	10
Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression	10
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction	10
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project	10
Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer	10
Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis	10
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis	10
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors	10
Reply to Bourgeois P.	10
Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis	10
Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer	10
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey	10
Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review	10
The association between age at breast cancer diagnosis and prevalence of pathogenic variants	9
First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer	9
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis	9
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study	9
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer	9
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY	9
Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques	9
COVID-19 related change in breast cancer diagnosis, stage, treatment, and case volume: 2019–2021	9
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer	9
Letter to the BRCT editor	9
Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer	9
Postmenopausal overweight and breast cancer risk; results from the KARMA cohort	9
Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction	9
Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study	9
Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	9
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer	9
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system	9
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor	9
Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide c	9
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry	9
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?	9